Dabogratinib (TYRA-300) 60mg + Dabogratinib (TYRA-300) 80mg + Dabogratinib (TYRA-300) TBD
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Low Grade Upper Tract Urothelial Carcinoma
Conditions
Low Grade Upper Tract Urothelial Carcinoma
Trial Timeline
Dec 22, 2025 → Nov 1, 2030
NCT ID
NCT07265947About Dabogratinib (TYRA-300) 60mg + Dabogratinib (TYRA-300) 80mg + Dabogratinib (TYRA-300) TBD
Dabogratinib (TYRA-300) 60mg + Dabogratinib (TYRA-300) 80mg + Dabogratinib (TYRA-300) TBD is a phase 2 stage product being developed by Tyra Biosciences for Low Grade Upper Tract Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07265947. Target conditions include Low Grade Upper Tract Urothelial Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07265947 | Phase 2 | Recruiting |
Competing Products
20 competing products in Low Grade Upper Tract Urothelial Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [203Pb]VMT-α-NET | Perspective Therapeutics | Phase 1 | 25 |
| azenosertib | Zentalis Pharmaceuticals | Phase 2 | 44 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 44 |
| DS-1001b | Daiichi Sankyo | Phase 2 | 52 |
| Rabeprazole Sodium | Eisai | Pre-clinical | 23 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 52 |
| Abemaciclib + Letrozole | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib + Mosunetuzumab | Eli Lilly | Phase 2 | 52 |
| Pembrolizumab + Pemetrexed + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| DSP-0390 | Sumitomo Pharma | Phase 1 | 33 |
| Mirvetuximab soravtansine + Carboplatin | AbbVie | Phase 2 | 52 |
| Mirvetuximab Soravtansine | AbbVie | Phase 2 | 52 |
| Acalabrutinib + Obinutuzumab | AstraZeneca | Phase 2 | 52 |
| Olaparib Pill + AZD6738 | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Efineptakin alfa + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel | Merck | Phase 2 | 52 |
| Cilengitide | Merck | Phase 2 | 52 |
| Avelumab | Merck | Phase 2 | 52 |
Other Products from Tyra Biosciences
TYRA-300 0.125 mg/kg + TYRA-300 0.25 mg/kg + TYRA-300 0.375 mg/kg + TYRA-300 0.50 mg/kgPhase 2
47
TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBDPhase 2
47
TYRA-300Phase 1/2
36
TYRA-430Phase 1
28
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles + Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cyclesPhase 1
28